<DOC>
	<DOCNO>NCT02843945</DOCNO>
	<brief_summary>Initial study evaluate local control prefer method attachment CivaSheet setting suspect close positive margin time surgical tumor removal .</brief_summary>
	<brief_title>Initial Feasibility Study Treat Pancreatic Cancer With Planar LDR Source</brief_title>
	<detailed_description>This Feasibility study determine safety efficacy new brachytherapy device provide unidirectional radiation utilizes active component ( Palladium-103 ) standard device novel configuration.This pilot study may benefit pancreatic cancer patient reduce radiation dose adjacent critical structure , give therapeutic dose diseased tissue , surgical margin . The appropriate dose local control rate record primary endpoint order provide efficacy assessment .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>â€¢ Subject sign inform consent Age &gt; 18 year Not pregnant breast feeding Patient capable undergoing anesthesia Patient select undergo Whipple procedure Patient metastatic disease Patients suspect R0 R1 margin No prior radiation therapy region separate cancer Confirmed diagnosis borderline resectable locally advanced pancreatic adenocarcinoma Patient Received neoadjuvant chemoradiation ( 4108 week prior surgery ) Induction chemotherapy administer combination follow agent : Gemcitabine + nbpaclitaxel FOLFIRINOX Neoadjuvant Chemordiation administer IMRT 3DCRT wPreoperative External beam dose ( NCCN ) 50.454 Gy ( 1.82.0 Gy per fraction ) concurrent gemcitabine , capecitabine , infusional 5fluorouracil Not surgical candidate Any invasive cancer past 5 year , except basal cell skin An IRE candidate ( IRE Percutaneous irreversible electroporation ) Recurrent previously resect tumor Documented History Alcoholism drug abuse Participant clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>